124 related articles for article (PubMed ID: 3023614)
21. Permanently charged chiral 1,4-dihydropyridines: molecular probes of L-type calcium channels. Synthesis and pharmacological characterization of methyl(omega-trimethylalkylammonium) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate iodide, calcium channel antagonists.
Peri R; Padmanabhan S; Rutledge A; Singh S; Triggle DJ
J Med Chem; 2000 Jul; 43(15):2906-14. PubMed ID: 10956198
[TBL] [Abstract][Full Text] [Related]
22. New 1,4-dihydropyridine derivatives combining calcium antagonism and alpha-adrenolytic properties.
Marciniak G; Delgado A; Leclerc G; Velly J; Decker N; Schwartz J
J Med Chem; 1989 Jun; 32(6):1402-7. PubMed ID: 2542561
[TBL] [Abstract][Full Text] [Related]
23. New 1,4-dihydropyridines with vasoconstrictor action through activation of Ca++-channels.
Takenaka T; Inagaki O; Terai M; Asano M; Kubo K
J Pharmacol Exp Ther; 1988 Feb; 244(2):699-708. PubMed ID: 2450201
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and calcium channel antagonist activity of nifedipine analogues containing 1,2-dihydropyridyl in place of the 1,4-dihydropyridyl moiety.
Soboleski DA; Li-Kwong-Ken MC; Wynn H; Triggle CR; Wolowyk MW; Knaus EE
Drug Des Deliv; 1988 Feb; 2(3):177-89. PubMed ID: 2855573
[TBL] [Abstract][Full Text] [Related]
25. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors.
Thayer SA; Welcome M; Chhabra A; Fairhurst AS
Biochem Pharmacol; 1985 Jan; 34(2):175-80. PubMed ID: 2981533
[TBL] [Abstract][Full Text] [Related]
26. Comparative actions of dihydropyridine slow channel calcium blocking agents in conscious dogs: systemic and coronary hemodynamics with and without combined beta adrenergic blockade.
Warltier DC; Zyvoloski MG; Gross GJ; Brooks HL
J Pharmacol Exp Ther; 1984 Aug; 230(2):367-75. PubMed ID: 6146711
[TBL] [Abstract][Full Text] [Related]
27. Studies on nilvadipine. I. Synthesis and structure-activity relationships of 1,4-dihydropyridines containing novel substituents at the 2-position.
Satoh Y; Ichihashi M; Okumura K
Chem Pharm Bull (Tokyo); 1991 Dec; 39(12):3189-201. PubMed ID: 1814611
[TBL] [Abstract][Full Text] [Related]
28. Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in conscious, renal-hypertensive dogs.
Karasawa A; Ikeda J; Yamada K; Kubo K; Oka T; Nakamizo N
Arzneimittelforschung; 1988 Nov; 38(11A):1695-7. PubMed ID: 3219142
[TBL] [Abstract][Full Text] [Related]
29. Binding of a calcium antagonist, [3H]nitrendipine, to high affinity sites in bovine aortic smooth muscle and canine cardiac membranes.
Williams LT; Tremble P
J Clin Invest; 1982 Jul; 70(1):209-12. PubMed ID: 6282938
[TBL] [Abstract][Full Text] [Related]
30. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs.
Kanda A; Haruno A; Miyake H; Nagasaka M
J Cardiovasc Pharmacol; 1992; 20(5):723-30. PubMed ID: 1280733
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological activity of the calcium modulator (R) and (S)-3-methyl 5-pentyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.
Zhang BL; He W; Shi X; Huan ML; Huang QJ; Zhou SY
Bioorg Med Chem Lett; 2010 Feb; 20(3):805-8. PubMed ID: 20064722
[TBL] [Abstract][Full Text] [Related]
32. Calcium entry activators: distinct sites of dihydropyridine and aminopyridine action.
Greenberg DA; Cooper EC; Carpenter CL
Neurosci Lett; 1984 Sep; 50(1-3):279-82. PubMed ID: 6208517
[TBL] [Abstract][Full Text] [Related]
33. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action.
Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M
Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619
[TBL] [Abstract][Full Text] [Related]
34. Nitrendipine potentiates Bay k 8644-induced contraction of isolated porcine coronary artery: evidence for functionally distinct dihydropyridine receptor subtypes.
Dube GP; Baik YH; Vaghy PL; Schwartz A
Biochem Biophys Res Commun; 1985 May; 128(3):1295-302. PubMed ID: 2408616
[TBL] [Abstract][Full Text] [Related]
35. Conformational features of calcium channel agonist and antagonist analogs of nifedipine.
Langs DA; Triggle DJ
Mol Pharmacol; 1985 May; 27(5):544-8. PubMed ID: 2581123
[TBL] [Abstract][Full Text] [Related]
36. Calcium entry blockers and oxiracetam have opposite effects on the density of dihydropyridine receptors in rat cerebral cortex.
Dudkin SM; Polev PV; Soldatov NM
Brain Res; 1990 Aug; 525(2):319-21. PubMed ID: 2174714
[TBL] [Abstract][Full Text] [Related]
37. Enantioselective syntheses and calcium channel modulating effects of (+)- and (-)-3-isopropyl 5-(4-methylphenethyll) 1,4-dihydro-2,6-dimethyl-4-(2-pyridyl)-3,5-pyridinedicarboxylates.
Iqbal N; Vo D; McEwen CA; Wolowyk MW; Knaus EE
Chirality; 1994; 6(7):515-20. PubMed ID: 7986665
[TBL] [Abstract][Full Text] [Related]
38. Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
Alker D; Campbell SF; Cross PE; Burges RA; Carter AJ; Gardiner DG
J Med Chem; 1990 Feb; 33(2):585-91. PubMed ID: 2153819
[TBL] [Abstract][Full Text] [Related]
39. Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
Rovnyak GC; Atwal KS; Hedberg A; Kimball SD; Moreland S; Gougoutas JZ; O'Reilly BC; Schwartz J; Malley MF
J Med Chem; 1992 Aug; 35(17):3254-63. PubMed ID: 1387168
[TBL] [Abstract][Full Text] [Related]
40. Crystal structures and pharmacologic activities of 1,4-dihydropyridine calcium channel antagonists of the isobutyl methyl 2,6-dimethyl-4-(substituted phenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nisoldipine) series.
Fossheim R; Joslyn A; Solo AJ; Luchowski E; Rutledge A; Triggle DJ
J Med Chem; 1988 Feb; 31(2):300-5. PubMed ID: 3339603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
